Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: A Hellenic Cooperative Oncology Group (HeCOG) study

Annals of Oncology

Volumn 20, Issue 8, 2009, Pages 1362-1368

  Mountzios, G ^a   Dimopoulos, M A ^a   Bamias, A ^a   Vourli, G ^b   Kalofonos, H ^c   Aravantinos, G ^d   Fountzilas, G ^e   Papadimitriou, C A ^a,f  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d AGII ANARGIRI CANCER HOSPITAL   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f NONE   (Greece)

Author keywords

Advanced cervical cancer; Cisplatinum; Ifosfamide; Neurotoxicity; Paclitaxel; Triplet combination

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; UTERINE CERVIX CARCINOMA; ADULT; AGED; DRUG ADMINISTRATION; FEMALE; METASTASIS; MIDDLE AGED; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MESNA; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; UTERINE CERVICAL NEOPLASMS;

EID: 69449106007     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn797     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Vermorken JB, Zanetta G, De Oliveira CF et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study. Ann Oncol 2001; 12(7): 967-974.
3. Long HJ III. Management of metastatic cervical cancer: Review of the literature. J Clin Oncol 2007; 25: 2966-2974.
4. Cadron I, Van GT, Amant F et al. Chemotherapy for recurrent cervical cancer. Gynecol Oncol 2007; 107: S113-S118.
5. Thigpen T, Stehman FB, Homesley H. Cancers of the uterine cervix and endometrium: Major issues and future research directions. Semin Oncol 1994; 21: 114-118.
6. Bonomi P, Blessing JA, Stehman FB et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-1085.
7. Alberts DS, Kronmal R, Baker LH et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group Study. J Clin Oncol 1987; 5(11): 1791-1795.
8. Sutton GP, Blessing JA, Adcock L et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1989; 7: 341-343.
9. Sutton GP, Blessing JA, McGuire WP et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecologic Oncology Group study. Am J Obstet Gynecol 1993; 168: 805-807.
10. Cervellino JC, Araujo CE, Pirisi C et al. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology 1991; 48: 89-92.
11. Bookman MA, Blessing JA, Hanjani P et al. Topotecan in squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77: 446-449.
12. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol 2001; 81: 213-215.
13. McGuire WP, Blessing JA, Moore D et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-795.
14. Kudelka AP, Winn R, Edwards CL et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8: 657-661.
15. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2001; 19: 1275-1278.
16. Schilder RJ, Blessing JA, Morgan M et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group. Gynecol Oncol 2000; 76: 204-207.
17. Lhomme C, Vermorken JB, Mickiewicz E et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 2000; 36: 194-199.
18. Brader KR, Morris M, Levenback C et al. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design. J Clin Oncol 1998; 16: 1879-1884.
19. Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix, a Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 165-171.
20. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 2004; 22: 3113-3119.
21. Long HJ III, Bundy BN, Grendys EC Jr et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-4633.
22. Van Luijk IF, Coens C, van der Burg ME et al. Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol 2007; 18(2): 275-281.
23. Dimopoulos MA, Papadimitriou CA, Sarris K et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: A phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 2002; 85: 476-482.
24. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24: 3245-3251.
25. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8: 1935-1937.
26. Coppin CM. The description of chemotherapy delivery: Options and pitfalls. Semin Oncol 1987; 14: 34-42.
27. Papadimitriou CA, Sarris K, Moulopoulos LA et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999; 17: 761-766.
28. Cervellino JC, Araujo CE, Sanchez O et al. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 1995; 34: 257-259.
29. Coleman RE, Clarke JM, Slevin ML et al. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1990; 27: 52-54.
30. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 1990; 17: 2676-2680.
31. Piver MS, Ghamande SA, Eltabbakh GH, O'Neill-Coppola C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - a phase II study. Gynecol Oncol 1999; 75: 334-337.
32. Monk BJ, Sill M, McMeekin DS et al. A randomized phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: A Gynecologic Oncology Group study. Presented at ASCO 2008. (Abstr LBA 5504).